Amgen to end controversial anemia-drug sales practices

It’s been a while since we heard much about Amgen’s struggling anemia-drug franchise. But this morning’s New York Times brings word that the company is changing a couple of pricing practices that some critics have argued encouraged overuse of the drugs ...Amgen kills anemia drug rebates FiercePharmaAmgen (AMGN) to Halt Discounts on Aranesp -NYTimes StreetInsider.com (subscription)Hays Pharma - Seattle Post Intelligencer - Pharmalot - New York Times